BioSmart Research, Inc.

BioSmart Research: Invest in the future of cannabinoid therapy.

https://wefunder.com/biosmart.research.inc

Total raised on Wefunder: 53200

Total investors: 21

Quick facts

  • Launch in 2019 produced $1.7M in sales
  • Biosmart produces pain management and anti-anxiety formulas for clinical and retail distribution
  • BioSmart has a 3-year technology lead using high-pressure liquid chromatography for isolate extraction
  • BioSmart markets through it's own retail dispensaries, healthcare providers, pharmacies, affiliates, and internet sales
  • U.S. Market for non-steroidal OTC pain relievers is $21.9 B/yr. US CBD market is $4.7 B/yr.
  • Clinical dosing levels with CBD isolates produce similar results to OTC pain relievers without the side effects.
  • BioSmart collaborates with university and clinical researchers and is a member of Choose Wisely, a patient forum
  • BioSmart Research represents a responsible approach to improving quality of life and advancing cannabinoid research

Team profiles

Featured investor profiles

BioSmart Research, Inc.

BioSmart Research: Invest in the future of cannabinoid therapy

Funded badge
Last Funded December 2021

$53,200

raised from 21 investors
Pitch Video
Investor Panel

Investor Panel

Brian and Jacob interviewed BioSmart Research, Inc. on July 2, 2021. Play Video
Brian Ballan
Brian Ballan
Founder in CPG. Most excited about climate friendly agriculture, decarbonization, and regional food systems.
Jacob Brutman
Jacob Brutman
Angel Investor, Ph.D. Chemist and Computer Enthusiast
Strengths
says, "The patentable formulations of CBD that can be shown to work have potential to be blockbusters."
says, "Company founder knows her stuff. Answered scientific questions with ease."
Advice
says, "Going to market through gatekeepers like physicians and clinics can be tough to crack, but also creates a great moat when done well."
says, "Get scientific studies done on your CBD to show it’s efficacy."

What Investors Say

LEAD INVESTOR
Invested $25,000 this round
I am a Pediatric ICU physician and I have also been seeing very complex pediatric and adult patients to discuss the use of medical cannabis for the last 6 years. As an ICU physician, we use medications, technology, and lab testing every day. For the most part, it is never questioned and for that matter completely trusted. In the cannabis space, and most specifically the CBD space, this has not been the case. I have spent the last several years performing my own testing on cannabinoids, trying out products myself, and relying on the COA's and the data from a lot of the existing companies. This process, unfortunately, has been a misleading and distrustful process. I have come to know Renee Searle and the list of persons associated with BioSmart and their scientific knowledge is excellent, up to date, and their equipment and extraction methods are of the utmost importance. BioSmart has changed and will continue to change the CBD market and will allow the consumer to purchase a pure cannabinoid, an exact mg measurement, and a consistent product that will enable the patient to have improved symptom and disease management.
What People Say